Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease
Clinical trial NCT06462469 · RECRUITING
Trial details
- NCT number
- NCT06462469
- Sponsor
- Novartis Pharmaceuticals
- Status
- RECRUITING
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-04
- Primary completion
- 2026-09-24
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.